Delivering Imaging to Pharmaceutical Standards
Bioxydyn designs and delivers quantitative MRI biomarker studies for pharmaceutical and clinical research. We generate robust, decision-ready imaging data across early-phase and multi-centre trials.
All Bioxydyn studies are managed through VoxelFlow, our proprietary imaging data platform.
VoxelFlow provides a secure, end-to-end, 21 CFR Part 11 framework for imaging study delivery. From site upload and quality control through to quantitative analysis and statistical output, the platform ensures traceability, version control, and consistent processing across all sites and timepoints. Learn more about VoxelFlow.
We specialise in quantitative MRI biomarkers that measure disease biology and treatment response. Our team has deep experience in developing, validating, and applying advanced imaging techniques across multiple therapeutic areas. We translate complex imaging science into reproducible, high-quality datasets that support confident development decisions. See what we do in MRS.
We work with sponsors from the earliest stages of study planning to ensure imaging endpoints are scientifically sound and tailored exactly with your programme objectives.
Our support includes:
Successful imaging studies require more than technology. They require coordination, training, and clear real-time communication.
Bioxydyn provides dedicated project management for every study, ensuring seamless collaboration between sponsors, CRO partners, and imaging sites. We support sites with structured training, ongoing guidance, and responsive technical assistance to maintain protocol adherence and data quality throughout the trial.
Our approach includes:
